查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1169046

注意力缺陷多动障碍治疗市场：按药物类型（兴奋剂、非兴奋剂）、年龄组、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030 年

Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants, Non-stimulants ), by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 181 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球注意力缺陷多动障碍 (ADHD) 治疗市场包括用于治疗注意力缺陷多动障碍的治疗剂。 治疗包括多种兴奋剂，如苯丙胺、□醋甲酯、右旋苯丙胺、右旋□醋甲酯和二甲磺酸利右苯丙胺，以及非兴奋剂，如托莫西汀、安非他酮、胍法辛和可乐定。 注意力缺陷多动障碍 (ADHD) 分为三种类型：注意力不集中为主、多动衝动为主和两者兼有。 注意缺陷多动障碍 (ADHD) 的病因很多，包括脑损伤、怀孕期间饮酒和吸烟、早产和低出生体重。 注意力缺陷多动障碍是一种影响数百万儿童的慢性疾病，并且经常持续到成年期。 患有註意力缺陷多动障碍的儿童经常在学校表现不佳和自尊心低下。 注意力缺陷多动障碍无法治愈，但可以控制症状。 注意缺陷多动障碍的治疗包括行为干预和药物治疗。 多动症主要有註意力不集中的症状。 ADHD 可能会增加患 ADHD 的风险，这可能是遗传等多种因素共同作用的结果，研究人员正在研究脑部疾病、营养和社会环境如何在 ADHD 中发挥作用。我正在寻找可能的环境因素。

市场动态

主要参与者正专注于技术进步，以巩固其在全球注意力缺陷多动障碍 (ADHD) 治疗市场的地位。 例如，2020 年 6 月，数字药物处方公司 Akili Interactive Labs 的 EndeavorRx□ (AKL-T01) 获得了美国食品和药物管理局的批准，这是一种治疗注意力缺陷多动障碍 (ADHD) 儿童的处方药。我得到了 EndeavorRxTM 用于治疗和改善多动症儿童的注意力。

这项研究的主要特点

  • 本报告对全球注意力缺陷多动障碍治疗市场进行了深入分析，包括以 2021 年为基准年的预测期 (2022-2030) 的市场规模和復合年增长率 (CAGR%)。 .
  • 它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
  • 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
  • 根据公司亮点、产品组合、主要亮点、财务业绩和战略等参数介绍全球注意力缺陷多动障碍治疗市场主要参与者的概况。
  • 本研究涵盖的主要公司包括 Amnel Pharmaceuticals LLC.、Eli Lilly And Company、Johnson & Johnson Services, Inc.、Noven Pharmaceuticals, Inc.、RespireRx Pharmaceuticals Inc、Otsuka Pharmaceutical Co., Ltd.、Neos Therapeutics , Inc.、American Brivision (Holding) Corporation、Novartis AG、Takeda Pharmaceutical Company Limited、GSK plc、Purdue Pharma L.P.、Cingulate、Adlon Therapeutics L.P.、Tris Pharma, Inc.、Neuraxpharm、Supernus Pharmaceuticals, Inc. 和 Aytu Biopharma，公司
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
  • 全球注意力缺陷多动障碍治疗市场报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球注意力缺陷多动障碍治疗市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第2章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 市场概况：按药物类型
    • 市场概况：按年龄组
    • 市场概况：按分销渠道
    • 市场概况：按地区
  • 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

  • 市场动态
    • 司机
    • 约束因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 近期趋势
  • 收购和合作场景
  • 监管情景
  • 定价分析
  • 品牌映射
  • 管道分析
  • 害虫分析

第 4 章註意力缺陷多动障碍治疗的全球市场：冠状病毒 (COVID-19) 大流行的影响

  • 总体影响
  • 对供需的影响
  • COVID-19 对市场的影响

第 5 章註意力缺陷多动障碍治疗的全球市场：按药物类型分列，2017-2030

  • 兴奋剂
  • 苯丙胺
  • □醋甲酯
  • 右旋苯丙胺
  • □醋甲酯
  • Lizdexamfetamine 二甲磺酸盐
  • 无刺激性
  • 托莫西汀
  • 安非他酮
  • 光华申
  • 可乐定

第 6 章註意力缺陷多动障碍治疗的全球市场：按年龄组划分，2017-2030

  • 童年和青春期
  • 成人

第 7 章。全球注意力缺陷多动障碍治疗市场：按分销渠道，2017-2030

  • 医院药房
  • 零售药房
  • 在线药店

第 8 章註意力缺陷多动障碍治疗的全球市场：按地区划分，2017-2030

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第9章竞争格局

  • Amnel Pharmaceuticals LLC.
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neos Therapeutics, Inc.
  • American Brivision（Holding）Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Purdue Pharma L.P.
  • Cingulate
  • Adlon Therapeutics L.P.
  • Tris Pharma, Inc.
  • Neuraxpharm
  • Supernus Pharmaceuticals, Inc.
  • Aytu Biopharma, Inc.

第10章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI830

The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD.

Market Dynamics

Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD.

Key features of the study:

  • This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market

Detailed Segmentation:

  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type:
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Dexmethylphenidate
      • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Atomoxetine
      • Bupropion
      • Guanfacine
      • Clonidine
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group:
    • Pediatric and Adolescent
    • Adult
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Amnel Pharmaceuticals LLC.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Eli Lilly And Company
    • Johnson & Johnson Services, Inc.
    • Noven Pharmaceuticals, Inc.
    • RespireRx Pharmaceuticals Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Neos Therapeutics, Inc.
    • American Brivision (Holding) Corporation
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • GSK plc
    • Purdue Pharma L.P.
    • Cingulate
    • Adlon Therapeutics L.P.
    • Tris Pharma, Inc.
    • Neuraxpharm
    • Supernus Pharmaceuticals, Inc.
    • Aytu Biopharma, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Age Group
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Pricing Analysis
  • Brand Mapping
  • Pipeline Analysis
  • PEST Analysis

4. Global Attention Deficit Hyperactivity Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Impact on Supply and Demand
  • COVID-19 Impact on the market

5. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Stimulants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-Stimulants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine

6. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Pediatric and Adolescent
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Amnel Pharmaceuticals LLC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neos Therapeutics, Inc.
  • American Brivision (Holding) Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Purdue Pharma L.P.
  • Cingulate
  • Adlon Therapeutics L.P.
  • Tris Pharma, Inc.
  • Neuraxpharm
  • Supernus Pharmaceuticals, Inc.
  • Aytu Biopharma, Inc.

10. Section

  • Research Methodology
  • About Us